The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After…

Overview of attention for article published in Annals of Surgical Oncology, September 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#19 of 6,936)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 35 news outlets

twitter: 2 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 3 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 35 news stories from 35 outlets.

New Neoadjuvant Trial Confirms the Predictive Utility of MammaPrint® + BluePrint®

AP News, 28 Sep 2023

Study shows that patients with genomically high-risk breast cancer, as defined by MammaPrint with or without BluePrint, respond…

New Neoadjuvant Trial Confirms the Predictive Utility of MammaPrint® + BluePrint®

IT News Online, 28 Sep 2023

PR Newswire. All Rights Reserved 2023-09-28 Study shows that patients with genomically high-risk breast cancer, as defined by…

New Neoadjuvant Trial Confirms the Predictive Utility of MammaPrint® + BluePrint®

WDAM - TV, 28 Sep 2023

Study shows that patients with genomically high-risk breast cancer, as defined by MammaPrint with or without BluePrint, respond…

New Neoadjuvant Trial Confirms the Predictive Utility of MammaPrint® + BluePrint®

South Carolina News Now, 28 Sep 2023

Study shows that patients with genomically high-risk breast cancer, as defined by MammaPrint with or without BluePrint, respond…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 31 additional news stories.